Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. (2021)
Journal Article
Tree, J., Turnbull, J., Buttigieg, K., Elmore, M., Coombes, N., Hogwood, J., Mycroft-West, C., Andrade De Lima, M., Skidmore, M., Karlsson, R., Chen, Y.-H., Yang, Z., Spalluto, C., Staples, K., Yates, E., Gray, E., Singh, D., Wilkinson, T., Page, C., & Carroll, M. (2021). Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. British Journal of Pharmacology, 178, 626--635. https://doi.org/10.1111/bph.15304

BACKGROUND AND PURPOSE: Currently, there are no licensed vaccines and limited antivirals for the treatment of COVID-19. Heparin (delivered systemically) is currently used to treat anticoagulant anomalies in COVID-19 patients. Additionally, in the Uni... Read More about Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations..